Bio Products Laboratory Bpl

UPS Invests $48 Million in Global Cold Chain Expansion to Meet Surging Biologics Demand

- UPS commits $48 million to expand temperature-controlled freight cross-dock facilities across 27 locations in Europe, Asia, and the Americas. - The investment targets the growing $39.1 billion temperature-sensitive biologics market, driven by GLP-1 injectables, cell and gene therapies, and mRNA platforms. - Temperature control failures account for 50% of global vaccine waste and cost an estimated $35 billion annually, according to the World Health Organization. - The expansion strengthens UPS's end-to-end cold chain capabilities as the company's healthcare portfolio reached $3 billion in quarterly revenue for the first time.